Dry Eye SyndromesNCT02356341
NovaTears® Eye Drops Observational Study NT-002
An observational study of Dry Eye Syndromes, run by Novaliq GmbH at 8 sites in Germany.
Trial summary
This observational study is intended to collect outcome data from a cohort of 90 patients suffering from symptoms of dry eye disease due to meibomian gland dysfunction who are treated with the medical device NovaTears® eye drops for a duration of 6 to 8 weeks. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Dry Eye Syndromes
- What is being tested?
- NovaTears® Eye Drops
- Type of treatment
- Medical device
- How many people
- 72 participants
- Where
- 8 sitesGermany
- Study dates
- Jan 2015to Dec 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with dry eye disease due to meibomian gland dysfunction
Who may be able to join
- According to NovaTears® instruction for use
- ≥ 18 years
- Patients with dry eye disease due to meibomian gland dysfunction applying eye lid hygiene for at least 14 days
- Ability and willingness to provide written Informed Consent
- Ability and willingness to participate in all examinations
- Willingness and ability to return for follow up visit
Who cannot join
- Patients with hypersensitivity to any of the components of NovaTears®
- Patients with contact lenses, pregnancies, or who are breast feeding
- Patients with dry eye disease not caused by meibomian gland dysfunction
- Patients taking lipid containing eye drops or requiring topical pharmacological treatment of dry eye disease
Trial locations and contacts
8 sites in 1 country.
8 sites in 1 country
Germany8 sites
Prof. Dr. Norbert Schrage
Cologne, 50765
University Eye Hospital of the HHU Duesseldorf
Düsseldorf, 40225
University Eye Hospital of the FAU Erlangen-Nuremberg
Erlangen, 91054
University Eye Hospital Heidelberg
Heidelberg, 69120
Dr. Thomas Kaercher
Heidelberg, 69121
JenVis Research Institute
Jena, 07745
Staedtisches Klinikum Karlsruhe
Karlsruhe, 76133
University Eye Hospital, LMU Munich
Munich, 80336
About this study
Official title: NovaTears® Observational Study NT-002
This observational study is intended to collect outcome data from a cohort of 90 patients suffering from symptoms of dry eye disease due to meibomian gland dysfunction who are treated with the medical device NovaTears® eye drops for a duration of 6 to 8 weeks.
- Conditions
- Dry Eye Syndromes
- Being tested
- NovaTears® Eye Drops
- Medical subject headings
- Dry Eye Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NovaTears® Eye DropsDevice
Topical eye drops for lubrication of the ocular surface
| Study group | Role | What they receive |
|---|---|---|
| NovaTears® | Not described Receives: Device: NovaTears® Eye Drops |
What is being measured
The primary outcome is the main question the study is designed to answer.
Subjective symptom severity
Change in subjective symptom severity score compared to Baseline
Measured: 6 to 8 weeks
Secondary outcomes (1)
Tear-Film Break-up Time
Change in Tear Film Break-up Time (measured in seconds) compared to Baseline
Measured: 6 to 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2015 (estimated)
- Study startJan 2015
- Primary completionDec 2015
- Study completionDec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Dry Eye SyndromesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 72 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novaliq GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novaliq GmbH, Study director, Novaliq GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02356341
- Sponsor's protocol ID
- NT-002
- Status last verified
- Mar 2016
- First submitted
- 21 Jan 2015
- Last updated
- 9 Mar 2016
- Results posted
- No
- Data monitoring committee
- No
Publications
Steven P, Augustin AJ, Geerling G, Kaercher T, Kretz F, Kunert K, Menzel-Severing J, Schrage N, Schrems W, Krosser S, Beckert M, Messmer EM. Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease. J Ocul Pharmacol Ther. 2017 Nov;33(9):678-685. doi: 10.1089/jop.2017.0042. Epub 2017 Sep 18.
PubMed 28922088
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- NovaTears® Observational Study NT-002
- ClinicalTrials.gov ID
- NCT02356341
- Acronym / sponsor ID
- NT-002
- Conditions
- Dry Eye Syndromes
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 72 participants (actual)
- Lead sponsor
- Novaliq GmbHIndustry (pharma, biotech, devices)
- Study start
- Jan 2015
- Primary completion
- Dec 2015 (actual)
- Study completion
- Dec 2015 (actual)
- First posted
- 5 Feb 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study is intended to collect outcome data from a cohort of 90 patients suffering from symptoms of dry eye disease due to meibomian gland dysfunction who are treated with the medical device NovaTears® eye drops for a duration of 6 to 8 weeks.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| NovaTears® | – | Device: NovaTears® Eye Drops |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with dry eye disease due to meibomian gland dysfunction
Key inclusion criteria (6 listed)
- According to NovaTears® instruction for use
- ≥ 18 years
- Patients with dry eye disease due to meibomian gland dysfunction applying eye lid hygiene for at least 14 days
- Ability and willingness to provide written Informed Consent
- Ability and willingness to participate in all examinations
Key exclusion criteria (4 listed)
- Patients with hypersensitivity to any of the components of NovaTears®
- Patients with contact lenses, pregnancies, or who are breast feeding
- Patients with dry eye disease not caused by meibomian gland dysfunction
- Patients taking lipid containing eye drops or requiring topical pharmacological treatment of dry eye disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NovaTears® Eye DropsTopical eye drops for lubrication of the ocular surface | Device | NovaTears® |
Primary outcome
Subjective symptom severity
Time frame: 6 to 8 weeks
Change in subjective symptom severity score compared to Baseline
1 secondary outcome
Tear-Film Break-up Time
Time frame: 6 to 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2016.
- Derived from this study: PubMed 28922088Steven P, Augustin AJ, Geerling G, Kaercher T, Kretz F, Kunert K, Menzel-Severing J, Schrage N, Schrems W, Krosser S, Beckert M, Messmer EM. Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease. J Ocul Pharmacol Ther. 2017 Nov;33(9):678-685. doi: 10.1089/jop.2017.0042. Epub 2017 Sep 18.
Related trials for Dry Eye Syndromes
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
Not yet recruitingPhase 2
Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments
Dry Eye Disease (DED), Graft-Versus-Host Disease(GVHD)
Recruiting
Evaluation of the Prevalence, and Immunological Characteristics of Small Fiber Neuropathy in Patients With Primary Sjögren's Syndrome
Sjögren's Syndrome, Small Fiber Neuropathy
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
Active, not recruitingPhase 3
Nipocalimab in Moderate to Severe Sjogren's Disease
Sjogrens Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novaliq GmbH study director
Novaliq GmbH
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dry Eye Syndromes, run by Novaliq GmbH at 8 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Mar 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Subjective symptom severity (time frame: 6 to 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02356341, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2016.